cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc2dzrrx
title: CCDC 2234100: Experimental Crystal Structure Determination

description: Related Article: Yaoyao Chen, Liwei Tang, Yi Liu, Tian Yang, Lina Hua, Xi Zeng, Junhua Luo, Zhihua Sun|2023|J.Mater.Chem.C|11|3981|doi:10.1039/D3TC00199G
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cjc7j
title: CCDC 2190467: Experimental Crystal Structure Determination

description: Related Article: Anupam Sarkar, Tanaya Kundu, Srinivasan Natarajan|2023|Inorg.Chem.|62|4417|doi:10.1021/acs.inorgchem.2c03859
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cjcbm
title: CCDC 2190470: Experimental Crystal Structure Determination

description: Related Article: Anupam Sarkar, Tanaya Kundu, Srinivasan Natarajan|2023|Inorg.Chem.|62|4417|doi:10.1021/acs.inorgchem.2c03859
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cjcfq
title: CCDC 2190473: Experimental Crystal Structure Determination

description: Related Article: Anupam Sarkar, Tanaya Kundu, Srinivasan Natarajan|2023|Inorg.Chem.|62|4417|doi:10.1021/acs.inorgchem.2c03859
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.25934/pr00005056.1
title: Available IPD datapackage for study 'A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor'

description: To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.
DOI: 10.25934/pr00007874
title: Addressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials.

description: Neuroendocrine neoplasms (NENs) are a type of abnormal and excessive growth of tissue, accounting for about 0.5% of all newly diagnosed malignancies. The worldwide incidence, which is on the rise, possibly due to improved awareness, is approximately 5.86/100,000 per year with a prevalence in the United States estimated around <200,000, which makes it an orphan disease. Pancreatic neuroendocrine neoplasm (Pan-NENs), represent less than 3% of primary pancreatic tumors and involve the pancreatic islet cell, a pancreatic cell that produces hormones (e.g., insulin and glucagon) that are secreted into the bloodstream to help control the level of glucose (sugar) in the blood (also called islet of Langerhans). The mainstay of treatment is surgery with curative intent, if possible. When surgery has no indication, chronic medical management is required. Among the approved options, sunitinib (SUN) represents a cornerstone in the therapeutical strategy on Pan-NENs, having showed a progression-free survival (PFS) doubling rate over placebo. PFS refers to the time during which a patient shows no signs or symptoms of the growth or the spreading of a tumor. However, soon or later, the onset of intrinsic or acquired resistance still represents the limiting criteria for a durable response.  
Metformin (MET) is one of the most popular oral glucose-lowering medications, widely considered to be the optimal initial therapy for patients with type 2 diabetes mellitus (DM2). Metformin has shown to exert an anti-tumor effect in solid tumors, including NENs. More in detail, MET has shown to inhibit tumor growth in Pan-NENs in preclinical models  [Vitali E, Cancers 2020] and is also associated with longer PFS in patients with Pan-NENs receiving everolimus, a drug used as an immunosuppressant to prevent rejection of organ transplants and as a targeted therapy in the treatment of several solid tumours [Pusceddu, Gastroenterology 2018]. Additionally, MET has shown safety and efficacy in improving outcomes even when combined with sunitinib in renal cell carcinoma. 
Neverthless, limited data are available on a possibile  role of MET in patients with Pan-NENs treated with antiangiogenic targeted agents, like sunitinib.
Basically, the aim of this analysis is to evaluate if the association between the MET and SUN improves survival in patients with advanced Pan-NETs.
DOI: 10.25934/pr00005069.1
title: Available IPD datapackage for study 'A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors'

description: This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those randomized to placebo received a tablet that looked similar but had no active drug. Neither the patient or the doctor knew whether the patient was receiving sunitinib or placebo. Patients were followed to determine the status and size of their tumors, survival, quality of life and safety of the drug. The study was designed to detect a 50% improvement in median PFS[Progression Free Survival] with 90% power and was to enroll 340 subjects. An interim analysis was planned when 130 events had occurred, and the final analysis was to be conducted when 260 events had occurred. Study A6181111 was stopped early during the enrollment period because of a clear and clinically meaningful improvement in efficacy for the sunitinib treatment arm as recommended by the DMC [Data Monitoring Committee]. The actual number of subjects enrolled was 171 and the actual number of PFS events recorded was 81 PFS events. The decision to terminate the study was not based on safety concerns related to sunitinib administration.
DOI: 10.5281/zenodo.7764362
title: Dataset from publication: Long-term changes in bloom dynamics of Southern and Central Baltic cold-water phytoplankton

description: This data set contains the output of the numerical ocean model GETM used in the publication "Long-term changes in bloom dynamics of Southern and Central Baltic cold-water phytoplankton"
description: {"references": ["Gr\u00e4we, U., Klingbeil, K., Kelln, J., & Dangendorf, S. (2019). Decomposing Mean Sea Level Rise in a Semi-Enclosed Basin, the Baltic Sea. Journal of Climate, 32(11), 3089\u20133108. https://doi.org/10.1175/JCLI-D-18-0174.1"]}
DOI: 10.5281/zenodo.7764361
title: Dataset from publication: Long-term changes in bloom dynamics of Southern and Central Baltic cold-water phytoplankton

description: This data set contains the output of the numerical ocean model GETM used in the publication "Long-term changes in bloom dynamics of Southern and Central Baltic cold-water phytoplankton"
description: {"references": ["Gr\u00e4we, U., Klingbeil, K., Kelln, J., & Dangendorf, S. (2019). Decomposing Mean Sea Level Rise in a Semi-Enclosed Basin, the Baltic Sea. Journal of Climate, 32(11), 3089\u20133108. https://doi.org/10.1175/JCLI-D-18-0174.1"]}
DOI: 10.6084/m9.figshare.22331239
title: Supplementary Material for: Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD

description: Introduction: For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patients with dialysis-dependent CKD (DD-CKD). Methods: We identified patients with PB utilization among those with prevalent DD-CKD using 2018-2019 Medicare Parts A/B/D data. Patients were assigned to cohorts based on primary (most frequently used) PB among calcium acetate, ferric citrate, lanthanum carbonate, sevelamer (hydrochloride and carbonate), sucroferric oxyhydroxide. We measured proportion of patients who were adherent (proportion of days covered &gt;80%) and persistent (patients whose last 90 days of outpatient dialysis reported PB use). Net switching rates were calculated as the difference between switches to and from the primary agent. Results: We identified 136,912 patients with PB use. Proportion of patients adherent ranged from 63.8% (lanthanum carbonate) to 67.7% (sevelamer) and persistent from 85.1% (calcium acetate) to 89.5% (ferric citrate). Most patients (73%) used the same PB throughout the study. Overall, 20.5% of patients experienced one switch and 2.3% two or more. Positive net switching rates were observed for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate (2% to 10%) but negative for sevelamer and calcium acetate (–2% to –7%). Discussion/Conclusion: Adherence and persistence rates were low with slight variation across PBs. Net positive switching occurred for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate. Further studies are needed to determine the reasons for these findings and could identify opportunities for better control of phosphate levels among patients with CKD.
DOI: 10.6084/m9.figshare.22331239.v1
title: Supplementary Material for: Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD

description: Introduction: For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patients with dialysis-dependent CKD (DD-CKD). Methods: We identified patients with PB utilization among those with prevalent DD-CKD using 2018-2019 Medicare Parts A/B/D data. Patients were assigned to cohorts based on primary (most frequently used) PB among calcium acetate, ferric citrate, lanthanum carbonate, sevelamer (hydrochloride and carbonate), sucroferric oxyhydroxide. We measured proportion of patients who were adherent (proportion of days covered &gt;80%) and persistent (patients whose last 90 days of outpatient dialysis reported PB use). Net switching rates were calculated as the difference between switches to and from the primary agent. Results: We identified 136,912 patients with PB use. Proportion of patients adherent ranged from 63.8% (lanthanum carbonate) to 67.7% (sevelamer) and persistent from 85.1% (calcium acetate) to 89.5% (ferric citrate). Most patients (73%) used the same PB throughout the study. Overall, 20.5% of patients experienced one switch and 2.3% two or more. Positive net switching rates were observed for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate (2% to 10%) but negative for sevelamer and calcium acetate (–2% to –7%). Discussion/Conclusion: Adherence and persistence rates were low with slight variation across PBs. Net positive switching occurred for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate. Further studies are needed to determine the reasons for these findings and could identify opportunities for better control of phosphate levels among patients with CKD.
DOI: 10.15479/at:ista:12497
title: Research data to: The rigid core and flexible surface of amyloid fibrils probed by magic-angle-spinning NMR spectroscopy of aromatic residues

description: Aromatic side chains are important reporters of the plasticity of proteins, and often form important contacts in protein–protein interactions. We studied aromatic residues in the two structurally homologous cross-β amyloid fibrils HET-s, and HELLF by employing a specific isotope-labeling approach and magic-angle-spinning NMR. The dynamic behavior of the aromatic residues Phe and Tyr indicates that the hydrophobic amyloid core is rigid, without any sign of "breathing motions" over hundreds of milliseconds at least. Aromatic residues exposed at the fibril surface have a rigid ring axis but undergo ring flips on a variety of time scales from nanoseconds to microseconds. Our approach provides direct insight into hydrophobic-core motions, enabling a better evaluation of the conformational heterogeneity generated from an NMR structural ensemble of such amyloid cross-β architecture.
DOI: 10.5281/zenodo.7765643
title: PD-L1 immunoexpression as an early predictive biomarker: an analysis in cases of Oral Potentially Malignant Disorder (OPMD) and Oral Squamous Cell Carcinoma (OSCC).

description: Master chart for Oral Potentially Premalignant and Oral Squamous Cell Carcinoma cases.
DOI: 10.5281/zenodo.7765642
title: PD-L1 immunoexpression as an early predictive biomarker: an analysis in cases of Oral Potentially Malignant Disorder (OPMD) and Oral Squamous Cell Carcinoma (OSCC).

description: Master chart for Oral Potentially Premalignant and Oral Squamous Cell Carcinoma cases.
DOI: 10.6084/m9.figshare.22331245
title: Supplementary Material for: Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD

description: Introduction: For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patients with dialysis-dependent CKD (DD-CKD). Methods: We identified patients with PB utilization among those with prevalent DD-CKD using 2018-2019 Medicare Parts A/B/D data. Patients were assigned to cohorts based on primary (most frequently used) PB among calcium acetate, ferric citrate, lanthanum carbonate, sevelamer (hydrochloride and carbonate), sucroferric oxyhydroxide. We measured proportion of patients who were adherent (proportion of days covered &gt;80%) and persistent (patients whose last 90 days of outpatient dialysis reported PB use). Net switching rates were calculated as the difference between switches to and from the primary agent. Results: We identified 136,912 patients with PB use. Proportion of patients adherent ranged from 63.8% (lanthanum carbonate) to 67.7% (sevelamer) and persistent from 85.1% (calcium acetate) to 89.5% (ferric citrate). Most patients (73%) used the same PB throughout the study. Overall, 20.5% of patients experienced one switch and 2.3% two or more. Positive net switching rates were observed for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate (2% to 10%) but negative for sevelamer and calcium acetate (–2% to –7%). Discussion/Conclusion: Adherence and persistence rates were low with slight variation across PBs. Net positive switching occurred for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate. Further studies are needed to determine the reasons for these findings and could identify opportunities for better control of phosphate levels among patients with CKD.
DOI: 10.6084/m9.figshare.22331245.v1
title: Supplementary Material for: Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD

description: Introduction: For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patients with dialysis-dependent CKD (DD-CKD). Methods: We identified patients with PB utilization among those with prevalent DD-CKD using 2018-2019 Medicare Parts A/B/D data. Patients were assigned to cohorts based on primary (most frequently used) PB among calcium acetate, ferric citrate, lanthanum carbonate, sevelamer (hydrochloride and carbonate), sucroferric oxyhydroxide. We measured proportion of patients who were adherent (proportion of days covered &gt;80%) and persistent (patients whose last 90 days of outpatient dialysis reported PB use). Net switching rates were calculated as the difference between switches to and from the primary agent. Results: We identified 136,912 patients with PB use. Proportion of patients adherent ranged from 63.8% (lanthanum carbonate) to 67.7% (sevelamer) and persistent from 85.1% (calcium acetate) to 89.5% (ferric citrate). Most patients (73%) used the same PB throughout the study. Overall, 20.5% of patients experienced one switch and 2.3% two or more. Positive net switching rates were observed for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate (2% to 10%) but negative for sevelamer and calcium acetate (–2% to –7%). Discussion/Conclusion: Adherence and persistence rates were low with slight variation across PBs. Net positive switching occurred for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate. Further studies are needed to determine the reasons for these findings and could identify opportunities for better control of phosphate levels among patients with CKD.
DOI: 10.6084/m9.figshare.22331248
title: Supplementary Material for: Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD

description: Introduction: For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patients with dialysis-dependent CKD (DD-CKD). Methods: We identified patients with PB utilization among those with prevalent DD-CKD using 2018-2019 Medicare Parts A/B/D data. Patients were assigned to cohorts based on primary (most frequently used) PB among calcium acetate, ferric citrate, lanthanum carbonate, sevelamer (hydrochloride and carbonate), sucroferric oxyhydroxide. We measured proportion of patients who were adherent (proportion of days covered &gt;80%) and persistent (patients whose last 90 days of outpatient dialysis reported PB use). Net switching rates were calculated as the difference between switches to and from the primary agent. Results: We identified 136,912 patients with PB use. Proportion of patients adherent ranged from 63.8% (lanthanum carbonate) to 67.7% (sevelamer) and persistent from 85.1% (calcium acetate) to 89.5% (ferric citrate). Most patients (73%) used the same PB throughout the study. Overall, 20.5% of patients experienced one switch and 2.3% two or more. Positive net switching rates were observed for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate (2% to 10%) but negative for sevelamer and calcium acetate (–2% to –7%). Discussion/Conclusion: Adherence and persistence rates were low with slight variation across PBs. Net positive switching occurred for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate. Further studies are needed to determine the reasons for these findings and could identify opportunities for better control of phosphate levels among patients with CKD.
DOI: 10.6084/m9.figshare.22331248.v1
title: Supplementary Material for: Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD

description: Introduction: For patients with chronic kidney disease (CKD), the need for phosphate binder (PB) treatment peaks at onset of dialysis. This real-world study assessed rates of PB utilization and switching in patients with dialysis-dependent CKD (DD-CKD). Methods: We identified patients with PB utilization among those with prevalent DD-CKD using 2018-2019 Medicare Parts A/B/D data. Patients were assigned to cohorts based on primary (most frequently used) PB among calcium acetate, ferric citrate, lanthanum carbonate, sevelamer (hydrochloride and carbonate), sucroferric oxyhydroxide. We measured proportion of patients who were adherent (proportion of days covered &gt;80%) and persistent (patients whose last 90 days of outpatient dialysis reported PB use). Net switching rates were calculated as the difference between switches to and from the primary agent. Results: We identified 136,912 patients with PB use. Proportion of patients adherent ranged from 63.8% (lanthanum carbonate) to 67.7% (sevelamer) and persistent from 85.1% (calcium acetate) to 89.5% (ferric citrate). Most patients (73%) used the same PB throughout the study. Overall, 20.5% of patients experienced one switch and 2.3% two or more. Positive net switching rates were observed for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate (2% to 10%) but negative for sevelamer and calcium acetate (–2% to –7%). Discussion/Conclusion: Adherence and persistence rates were low with slight variation across PBs. Net positive switching occurred for ferric citrate, sucroferric oxyhydroxide, and lanthanum carbonate. Further studies are needed to determine the reasons for these findings and could identify opportunities for better control of phosphate levels among patients with CKD.
DOI: 10.6084/m9.figshare.22331227.v1
title: 209individuals.vcf.gz

description: <em>Whole-genome variants dataset of 209 local chickens</em>
DOI: 10.34808/f2ab-wh51
title: Inflow of fly ash on selected geotechnical parameters of soft soils.

description: The reaserch presents the experimental results made on samples of soft soils  mixed with fly ash in different proportions (10%, 20%, 30%). The files contains the data directly from direct shear aparatus and oedometer.
DOI: 10.34808/rvq5-hd69
title: Physicochemical and photocatalytic data of Nb-doped faceted TiO2

description: Raw numerical data, obtained from the physicochemical measurements (XRD, DR-UV/Vis, EPR) and numerical data on photocatalytic activity (phenol degradation and 4-nitrophenol reduction) extracted from the HPLC-DAD results, obtained for the TiO2 nanoparticles that expose majority of the {0 0 1}, {1 0 0} or {1 0 1} facets and were doped with the nominal amounts of Nb: 0%, 0.5%, 1.0% and 1.5% at. relative to Ti. Additional text files with measurements details and calibrations are included.